Glenmark Pharmaceuticals (NSE:GLENMARK) Retained Earnings: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLENMARK Glenmark Pharmaceuticals Ltd NSE:GLENMARK
85 GF Score
Price ₹2,460.00
GF Value ₹2,188.90
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Glenmark Pharmaceuticals Retained Earnings?

Glenmark Pharmaceuticals NSE:GLENMARK -0.42% 85 Retained Earnings is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:GLENMARK with a GF Score™ of 85/100 and a GF Value™ of ₹2,188.90 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Glenmark Pharmaceuticals's retained earnings for the quarter that ended in Jun. 2026 was ₹0 Mil.

Glenmark Pharmaceuticals's quarterly retained earnings increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹98,816 Mil) but then declined from Mar. 2026 (₹98,816 Mil) to Jun. 2026 (₹0 Mil).

Glenmark Pharmaceuticals's annual retained earnings increased from Mar. 2024 (₹78,704 Mil) to Mar. 2025 (₹87,985 Mil) and increased from Mar. 2025 (₹87,985 Mil) to Mar. 2026 (₹98,816 Mil).


Glenmark Pharmaceuticals  (NSE:GLENMARK) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Glenmark Pharmaceuticals Retained Earnings Historical Data

* Premium members only.

The historical data trend for Glenmark Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glenmark Pharmaceuticals Retained Earnings Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 92,109.07 94,570.39 78,704.49 87,985.39 98,816.49

Glenmark Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 98,816.49 0.00
NSE:GLENMARK
85GF Score
Glenmark Pharmaceuticals Ltd NSE:GLENMARK
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glenmark Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of ₹0 Mil mean?
Glenmark Pharmaceuticals (NSE:GLENMARK) has a Retained Earnings of ₹0 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Glenmark Pharmaceuticals and its competitors.
Is Glenmark Pharmaceuticals' Retained Earnings too high?
Glenmark Pharmaceuticals' current Retained Earnings is ₹0 Mil. Overall, Glenmark Pharmaceuticals has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' Retained Earnings compare to ZTS?
Glenmark Pharmaceuticals' Retained Earnings of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Glenmark Pharmaceuticals and its competitors. Glenmark Pharmaceuticals's current Retained Earnings is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,188.90, compared to a current price of ₹2,460.00 — trading 12.4% above its estimated fair value. The current Retained Earnings is ₹0 Mil. Glenmark Pharmaceuticals' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current Retained Earnings is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?

Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued. The current stock price of ₹2,460.00 is trading 12.4% above its estimated GF Value™ of ₹2,188.90. GuruFocus considers Glenmark Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for NSE:GLENMARK:

  • Retained Earnings: ₹0 Mil
  • GF Value™: ₹2,188.90 vs. price of ₹2,460.00 (12.4% above fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Glenmark Pharmaceuticals Business Description

Other Exchanges 532296:India
Address B. D. Sawant Marg, Glenmark House, Chakala, Off Western Express Highway, Andheri (East), Mumbai, MH, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
85GF Score

Get the complete analysis for NSE:GLENMARK

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,460.00
Price
₹2,188.90
GF Value